Progression characteristics of the European Friedreich&apos;s Ataxia Consortium for Translational Studies (EFACTS): a 4-year cohort study

Progression marker of Parkinson’s disease: a 4-year multi-site imaging study

Brain Neurology Journ.

Burciu RG, Ofori E, Archer DB, Wu SS, Pasternak O, McFarland NR, Okun MS, Vaillancourt DE

doi: 10.1093/brain/awx146.

RECOMMENDED

Parkinson’s Disease

Baseline predictors for progression 4 years after Parkinson's disease diagnosis in the De Novo Parkinson Cohort (DeNoPa)

Mov Disord.

Mollenhauer B, Zimmermann J, Sixel-Döring F, Focke NK, Wicke T, Ebentheuer J, Schaumburg M, Lang E, Friede T, Trenkwalder C; DeNoPa Study Group

doi: 10.1002/mds.27492.

Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson's disease: a longitudinal cohort study and validation

Lancet Neurol.

Latourelle JC, Beste MT, Hadzi TC, Miller RE, Oppenheim JN, Valko MP, Wuest DM, Church BW, Khalil IG, Hayete B, Venuto CS

doi: 10.1016/

Parkinson’s Disease

Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study

Lancet Neurol.

Simuni T, Uribe L, Cho HR, Caspell-Garcia C, Coffey CS, Siderowf A, Trojanowski JQ, Shaw LM, Seibyl J, Singleton A, Toga AW, Galasko D, Foroud T, Tosun D, Poston K, Weintraub D, Mollenhauer B, Tanner CM, Kieburtz K, Chahine LM, Reimer A, Hutten SJ, Bressman S, Marek K, PPMI Investigators.

doi: 10.1016/S1474-4422(19)30319-9.Visit the original publication at ncbi.nlm.nih.gov

Multiple Sclerosis

Anti-inflammatory disease modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study

Eur J Neurol.

Lorscheider J, Kuhle J, Izquierdo G, Lugaresi A, Havrdova E, Horakova D, Hupperts R, Duquette P, Girard M, Prat A, Grand'Maison F, Grammond P, Sola P, Ferraro D, Trojano M, Ramo-Tello C, Lechner-Scott J, Pucci E, Solaro C, Slee M, Van Pesch V, Menoyo JLS, van der Walt A, Butzkueven H, Kappos L, Kalincik T; MSBase Study Group

doi: 10.1111/ene.13824.

Further Publications NeurologyFurther Publications Psychiatry

Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington's disease Young Adult Study (HD-YAS): a cross-sectional analysis

Lancet Neurol.

Scahill RI, Zeun P, Osborne-Crowley K, Johnson EB, Gregory S, Parker C, Lowe J, Nair A, O'Callaghan C, Langley C, Papoutsi M, McColgan P, Estevez-Fraga C, Fayer K, Wellington H, Rodrigues FB, Byrne LM, Heselgrave A, Hyare H, Sampaio C, Zetterberg H, Zhang H, Wild EJ, Rees G, Robbins TW, Sahakian BJ, Langbehn D, Tabrizi SJ

doi: 10.1016/S1474-4422(20)30143-5.

Aging and Cognitive Functions

Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study

Lancet Neurol.

Moss DJH, Pardiñas AF, Langbehn D, Lo K, Leavitt BR, Roos R, Durr A, Mead S; TRACK-HD investigators; REGISTRY investigators, Holmans P, Jones L, Tabrizi SJ

doi: 10.1016/S1474-4422(17)30161-8.

Aging and Cognitive FunctionsDementia

A 'Framingham-like' Algorithm for Predicting 4-Year Risk of Progression to Amnestic Mild Cognitive Impairment or Alzheimer's Disease Using Multidomain Information

J Alzheimers Dis.

Steenland K, Zhao L, John SE, Goldstein FC, Levey A, Alvaro A; Alzheimer’s Disease Neuroimaging Initiative

doi: 10.3233/JAD-170769.

Multiple Sclerosis

Long-term disability progression in primary progressive multiple sclerosis: a 15-year study

Brain.

Rocca MA, Sormani MP, Rovaris M, Caputo D, Ghezzi A, Montanari E, Bertolotto A, Laroni A, Bergamaschi R, Martinelli V, Comi G, Filippi M

doi: 10.1093/brain/awx250.

Neurology · Psychiatry

Progression characteristics of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS): a 4-year cohort study

Related content

Progression marker of Parkinson’s disease: a 4-year multi-site imaging study

Baseline predictors for progression 4 years after Parkinson's disease diagnosis in the De Novo Parkinson Cohort (DeNoPa)

Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson's disease: a longitudinal cohort study and validation

Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study

Anti-inflammatory disease modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study

Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington's disease Young Adult Study (HD-YAS): a cross-sectional analysis

Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study

A 'Framingham-like' Algorithm for Predicting 4-Year Risk of Progression to Amnestic Mild Cognitive Impairment or Alzheimer's Disease Using Multidomain Information

Long-term disability progression in primary progressive multiple sclerosis: a 15-year study